[1] Feng Z, Liu W, Jiang HX, et al. How does herbal medicine treat idiopathic membranous nephropathy?[J].Front Pharmacol,2020,11:994.DOI:10.3389/fphar.2020.00994.
[2] Xu X, Wang G, Chen N, et al. Long-term exposure to air pollution and increased risk of membranous nephropathy in China[J].J Am Soc Nephrol,2016,27(12):3739-3746.DOI:10.1681/ASN.2016010093.
[3] Chen Y, Schieppati A, Chen X, et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome[J].Cochrane Database Syst Rev,2014,2014(10):CD004293.DOI:10.1002/14651858.CD004293.pub3.
[4] 李平. 抗磷脂酶A2受体在特发性膜性肾病中的表达及临床意义[J]. 国际医药卫生导报,2018,24(4):494-497.DOI:10.3760/cma.j.issn.1007-1245.2018.04.011.
[5] Cashman KS, Jenks SA, Woodruff MC, et al. Understanding and measuring human B-cell tolerance and its breakdown in autoimmune disease[J].Immunol Rev,2019,292(1):76-89.DOI:10.1111/imr.12820.
[6] Devarapu SK, Lorenz G, Kulkarni OP, et al. Cellular and molecular mechanisms of autoimmunity and lupus nephritis[J].Int Rev Cell Mol Biol,2017,332:43-154.DOI:10.1016/bs.ircmb.2016.12.001.
[7] Papp G, Boros P, Nakken B, et al. Regulatory immune cells and functions in autoimmunity and transplantation immunology[J].Autoimmun Rev,2017,16(5):435-444.DOI:10.1016/j.autrev.2017.03.011.
[8] Thorlacius-Ussing G, Sørensen JF, Wandall HH, et al. Auto-reactive T cells revised. overestimation based on methodology?[J].J Immunol Methods,2015,420:56-59.DOI:10.1016/j.jim.2015.03.010.
[9] Spetz J, Presser AG, Sarosiek KA. T cells and regulated cell death: kill or be killed[J].Int Rev Cell Mol Biol,2019,342:27-71.DOI:10.1016/bs.ircmb.2018.07.004.
[10] Ding C, Yan J. Regulation of autoreactive B cells: checkpoints and activation[J].Arch Immunol Ther Exp (Warsz),2007,55(2):83-89.DOI:10.1007/s00005-007- 0011-0.
[11] Harbige J, Eichmann M, Peakman M. New insights into non-conventional epitopes as T cell targets: the missing link for breaking immune tolerance in autoimmune disease?[J].J Autoimmun,2017,84:12-20.DOI:10.1016/j.jaut.2017.08.001.
[12] Salinas GF, Braza F, Brouard S, et al. The role of B lymphocytes in the progression from autoimmunity to autoimmune disease[J].Clin Immunol,2013,146(1):34-45.DOI:10.1016/j.clim.2012.10.005.
[13] Tsai S, Santamaria P. Mhc class II polymorphisms, autoreactive T-cells, and autoimmunity[J].Front Immunol,2013,4:321.DOI:10.3389/fimmu.2013.00321.
[14] Königshausen E, Sellin L. Recent treatment advances and new trials in adult nephrotic syndrome[J].Biomed Res Int,2017,2017:7689254.DOI:10.1155/2017/7689254.
[15] Liu W, Gao C, Liu Z, et al. Idiopathic membranous nephropathy: glomerular pathological pattern caused by extrarenal immunity activity[J].Front Immunol,2020,11:1846.DOI:10.3389/fimmu.2020.01846.
[16] Stanescu HC, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy[J].N Engl J Med,2011,364(7):616-626.DOI:10.1056/NEJMoa1009742.
[17] Beck LH, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy[J].N Engl J Med,2009,361(1):11-21.DOI:10.1056/NEJMoa0810457.
[18] Tomas NM, Beck LH, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy[J].N Engl J Med,2014,371(24):2277-2287.DOI:10.1056/NEJMoa1409354.
[19] Sethi S, Debiec H, Madden B, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy[J].Kidney Int,2020,97(1):163-174.DOI:10.1016/j.kint.2019.09.014.
[20] Dong Y, Cao L, Tang H, et al. Structure of human m-type phospholipase A2 receptor revealed by cryo-electron microscopy[J].J Mol Biol,2017,429(24):3825-3835.DOI:10.1016/j.jmb.2017.10.019.
[21] Liu W, Gao C, Dai H, et al. Immunological pathogenesis of membranous nephropathy: focus on PLA2R1 and its role[J].Front Immunol,2019,10:1809.DOI:10.3389/fimmu.2019.01809.
[22] Ancian P, Lambeau G, Mattéi MG, et al. The human 180-kDa receptor for secretory phospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization[J].J Biol Chem,1995,270(15):8963-8970.DOI:10.1074/jbc.270.15.8963.
[23] van de Logt AE, Fresquet M, Wetzels JF, et al. The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery[J].Kidney Int,2019,96(6):1292-1302.DOI:10.1016/j.kint.2019.07.014.
[24] Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy[J].J Am Soc Nephrol,2005,16(5):1195-1204.DOI:10.1681/ASN.2004121098.
[25] Fogo AB, Lusco MA, Najafian B, et al. Ajkd atlas of renal pathology: membranous nephropathy[J].Am J Kidney Dis,2015,66(3):e15-e17.DOI:10.1053/j.ajkd.2015.07.006.
[26] Schiffer M, Teng B, Gu C, et al. Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models[J].Nat Med,2015,21(6):601-609.DOI:10.1038/nm.3843.
[27] Salant DJ, Belok S, Madaio MP, et al. A new role for complement in experimental membranous nephropathy in rats[J].J Clin Invest,1980,66(6):1339-1350.DOI:10.1172/JCI109987.
[28] Roccatello D, Sciascia S, Di Simone D, et al. New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: a prospective study and a review of the literature[J].Autoimmun Rev,2016,15(6):529-538.DOI:10.1016/j.autrev.2016.02.014.
[29] Ronco P, Debiec H. A podocyte view of membranous nephropathy: from Heymann nephritis to the childhood human disease[J].Pflugers Arch,2017,469(7-8):997-1005.DOI:10.1007/s00424-017-2007-x.
[30] Tomas NM, Hoxha E, Reinicke AT, et al. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy[J].J Clin Invest,2016,126(7):2519-2532.DOI:10.1172/JCI85265.
|
